Rolf Barth to Hepatitis C
This is a "connection" page, showing publications Rolf Barth has written about Hepatitis C.
Connection Strength
0.671
-
Safety of belatacept bridging immunosuppression in hepatitis C-positive liver transplant recipients with renal dysfunction. Transplantation. 2014 Jan 27; 97(2):133-7.
Score: 0.396
-
The Impact of Treatment Delay on Hepatitis C Liver Transplant Outcomes. J Pharm Pract. 2023 Apr; 36(2):264-270.
Score: 0.166
-
Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts. Transplantation. 2015 Jun; 99(6):1192-6.
Score: 0.109